NCT03241641View on ClinicalTrials.gov

Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.

PHASE4CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

October 26, 2017

Primary Completion Date

March 25, 2021

Study Completion Date

March 25, 2021

Conditions
Chronic Hepatitis b
Interventions
DRUG

Tenofovir Alafenamide

25mg, Daily Oral

DRUG

Tenofovir Disoproxil Fumarate

300mg, Daily Oral

Trial Locations (1)

05505

Asan Medical Center, Seoul

All Listed Sponsors
collaborator

Samsung Medical Center

OTHER

collaborator

Korea University Guro Hospital

OTHER

collaborator

Konkuk University Medical Center

OTHER

collaborator

Seoul National University Hospital

OTHER

lead

Young-Suk Lim

OTHER

NCT03241641 - Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir. | Biotech Hunter | Biotech Hunter